Technology | July 27, 2011

D3 Oncology Launches Program to Accelerate SRS/SBRT Implementations

 SABRE_Website

July 27, 2011 — D3 Oncology Solutions will begin offering a comprehensive product to radiation oncologists and surgeons to rapidly and safely implement a successful stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) program.

The product is called SABRE, based on the more accurate description of SBRT as stereotactic ablative radiation therapy (SABR). The program brings together essential components of a successful implementation of radiosurgery, including clinical training for surgeons and radiation oncology teams; accurate small-field dosimetry; peer-to-peer consultations; go-live support; reimbursement guidance; follow-up reviews of quality assurance; and claims accuracy with one of the nation's most experienced clinical and technical teams.

Despite the published patient benefits of SRS and SBRT, many cancer programs across the United States have not yet implemented this service line, even though most modern linear accelerators have capabilities to deliver radiosurgery.

"Engagement of surgeons in SRS/SBRT delivery is critical to program success but availability of training and certification is often limited. Additionally, the targeted nature of SRS/SBRT can be daunting for many physicians, especially in light of recent high-profile errors that resulted in patient injuries," said Ron LaLonde, Ph.D, DABR, chief scientific officer for D3 Oncology Solutions.

D3 is collaborating with the University of Pittsburgh Cancer Institute (UPCI), UPMC Cancer Centers and Revenue Cycle Inc., to provide best practices and peer-to-peer support for cancer centers and surgeons.  

"Our success with SRS/SBRT at UPMC Cancer Centers has been centered around the close collaboration between surgeons and radiation oncologists in the patient identification and care delivery process, providing options to patients who were not otherwise candidates for other treatment strategies," added Dwight Heron, M.D., professor of radiation oncology at the University of Pittsburgh School of Medicine and vice chairman of radiation oncology at UPCI.  "SABRE brings together the necessary knowledge and precise tools essential to replicate UPMC's SRS/SBRT success for cancer programs in other markets."

Finally, as part of a broader strategic collaboration, D3 has partnered with Revenue Cycle Inc., a radiation and medical oncology consultant, to bring programs for billing and coding training, claims accuracy review, verification of payment coverage and ongoing support for an extended period.  

For more information: www.d3onc.com

Related Content

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

News | Radiation Oncology | July 21, 2021
July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to...
ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images

News | Radiation Therapy | July 20, 2021
July 20, 2021 — In response to consecutive weeks of proposed...
Ramon Alfredo Siochi, Ph.D. — the director of medical physics at WVU — led a task group to help ensure the accuracy of data that dictates a cancer patient's radiation therapy.

Ramon Alfredo Siochi, director of medical physics at West Virginia University. Image courtesy of WVU Photo/Aira Burkhart

News | Radiation Oncology | July 15, 2021
July 15, 2021 — Just as helicopter traffic reporters use their "bird's eye view" to route drivers around roadblocks s
To help enhance the images and information provided to clinicians for radiation oncology treatment planning, GE Healthcare will integrate Spectronic Medical’s AI-based software with its industry leading AIR Recon DL technology
News | Artificial Intelligence | July 09, 2021
July 9, 2021 — GE Healthcare announced the integration of S...

Image courtesy of RaySearch

Feature | Treatment Planning | July 07, 2021 | Information provided by Grand View Research
RaySearch Laboratories AB announced an extension of its relationship with Centre hospitalier universitaire vaudois (CHUV) in Lausanne, Switzerland, which will include orders for RayStation RayCare and RayIntelligence. 
News | Oncology Information Management Systems (OIMS) | June 28, 2021
June 28, 2021 — RaySearch Laboratories AB announced an extension of its relationship with...
The two-year project focused on reducing the use of extended-fraction radiation therapy to treat pain from incurable cancer that had spread to patients’ bones. Once a standard practice, the American Society for Radiation Oncology (ASTRO) has recommended against the routine use of extended-fraction radiation to relieve pain from bone metastases, especially more than 10 treatments.

Multiple cancer metastasis to the pelvic bone and femur bones. Getty Images

News | Radiation Therapy | June 24, 2021
June 24, 2021 — An effort by the Michigan Radiation Oncology Quality Consortium ...
 Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11 with the MEVION S250i Proton Therapy System.

The teams from HCI, U of U and Mevion gather to celebrate the center’s grand opening. Group from left to right: Bill Salter, Ph.D., Senior Director of Radiation Oncology, HCI and Professor and Chief of the Division of Medical Physics, U of U -- Robyn Walker, Sr. Director, Customer Success and Service Operations, Mevion -- James Cooley, Ph.D., Director of Advanced Development, Mevion -- Dennis Shrieve, M.D., Ph.D., Chair in Cancer Research, HCI and Chair of Department of Radiation Oncology, U of U -- Tina Yu, Ph.D., CEO, Mevion -- Michael Good, M.D., Interim President, U of U and Sr. VP for Health Sciences, U of U Health -- Ying Hitchcock, M.D., Professor and Medical Director, Department of Radiation Oncology, U of U. (Photo: Business Wire)

News | Proton Therapy | June 24, 2021
June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin